Human Precision MEDicine (Hu-PreciMED) was created in an aim to structure the precision medicine industry in France. The project includes more than 45 digital and medical companies, and has a goal to bring together all public and private industry members and connect them to medical data from patients.
Precision medicine uses analysis of molecular and genetic characteristics to develop individualized or personalized treatment and monitoring. According to a press release, the industry is predicted to reach $96bn by 2024.
By connecting these companies with data, the project aims to improve the therapeutic and diagnostic tools currently available.
The project has three main areas each led by a specific coordinator. The components include: Target resolution led by Interesystems; investigation of new molecules by Servier; and preclinical and clinical development lead by Oncodesign.
The project will run in four phases, with the fourth expected to be complete in 2024.
The focus of the pilot program will be on immune-inflammatory diseases that affect 5-7% of the Western population with the goal of identifying the most relevant targets.
Two digital platforms will be used to manage the three components of the project, one for data integration and the other for data analysis.
Medicen Paris Region and Cap Digital are important players in the push advance the Hu-PreciMED project, as together the organizations have more than 1,400 members, and serve as competiveness clusters.
